These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 27270436)

  • 1. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
    Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
    Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative Genomic Analysis of OCT1 Reveals Coordinated Regulation of Androgen Receptor in Advanced Prostate Cancer.
    Takayama KI; Suzuki Y; Yamamoto S; Obinata D; Takahashi S; Inoue S
    Endocrinology; 2019 Feb; 160(2):463-472. PubMed ID: 30649323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
    Obinata D; Takayama K; Lawrence MG; Funakoshi D; Hara M; Niranjan B; Teng L; Taylor RA; Risbridger GP; Takahashi S; Inoue S
    BMC Cancer; 2024 May; 24(1):554. PubMed ID: 38698344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of pyrrole-imidazole polyamide modified with alkylating agent on prostate cancer cells.
    Funakoshi D; Obinata D; Fujiwara K; Yamamoto S; Takayama K; Hara M; Takahashi S; Inoue S
    Biochem Biophys Res Commun; 2022 Oct; 623():9-16. PubMed ID: 35868070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new octamer transcription factor 1-target genes upregulated in castration-resistant prostate cancer.
    Yamamoto S; Takayama KI; Obinata D; Fujiwara K; Ashikari D; Takahashi S; Inoue S
    Cancer Sci; 2019 Nov; 110(11):3476-3485. PubMed ID: 31454442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.
    Ponnusamy S; Coss CC; Thiyagarajan T; Watts K; Hwang DJ; He Y; Selth LA; McEwan IJ; Duke CB; Pagadala J; Singh G; Wake RW; Ledbetter C; Tilley WD; Moldoveanu T; Dalton JT; Miller DD; Narayanan R
    Cancer Res; 2017 Nov; 77(22):6282-6298. PubMed ID: 28978635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer.
    Obinata D; Takayama K; Urano T; Murata T; Kumagai J; Fujimura T; Ikeda K; Horie-Inoue K; Homma Y; Ouchi Y; Takahashi S; Inoue S
    Int J Cancer; 2012 Mar; 130(5):1021-8. PubMed ID: 21387309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.
    Wu M; Kim SH; Datta I; Levin A; Dyson G; Li J; Kaypee S; Swamy MM; Gupta N; Kwon HJ; Menon M; Kundu TK; Reddy GP
    Oncotarget; 2015 Mar; 6(8):6136-50. PubMed ID: 25704883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.
    He Y; Lu J; Ye Z; Hao S; Wang L; Kohli M; Tindall DJ; Li B; Zhu R; Wang L; Huang H
    Nucleic Acids Res; 2018 Feb; 46(4):1895-1911. PubMed ID: 29309643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
    Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
    Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence specific suppression of androgen receptor-DNA binding in vivo by a Py-Im polyamide.
    Kurmis AA; Dervan PB
    Nucleic Acids Res; 2019 May; 47(8):3828-3835. PubMed ID: 30838415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Chain Acyl-CoA Synthetase 4-Mediated Fatty Acid Metabolism Sustains Androgen Receptor Pathway-Independent Prostate Cancer.
    Ma Y; Zhang X; Alsaidan OA; Yang X; Sulejmani E; Zha J; Beharry Z; Huang H; Bartlett M; Lewis Z; Cai H
    Mol Cancer Res; 2021 Jan; 19(1):124-135. PubMed ID: 33077484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance.
    Li S; Hu MG; Sun Y; Yoshioka N; Ibaragi S; Sheng J; Sun G; Kishimoto K; Hu GF
    Mol Cancer Res; 2013 Oct; 11(10):1203-14. PubMed ID: 23851444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for targeting the androgen receptor axis in prostate cancer.
    Carver BS
    Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity.
    Wang J; Zhang H; Zhang X; Wang P; Wang H; Huang F; Zhou C; Zhou J; Li S
    Oncotarget; 2016 Dec; 7(49):81377-81388. PubMed ID: 27835608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.